Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Adicionar filtros








Intervalo de ano
1.
An. bras. dermatol ; 95(3): 271-277, May-June 2020. tab
Artigo em Inglês | LILACS, ColecionaSUS | ID: biblio-1130879

RESUMO

Abstract Finasteride is a 5α-reductase enzyme inhibitor that has been approved for the treatment of male androgenic alopecia since 1997. Over time, it has been considered a safe and well-tolerated drug with rare and reversible side effects. Recently there have been reports of adverse drug-related reactions that persisted for at least three months after discontinuation of this drug, and the term post-finasteride syndrome arose. It includes persistent sexual, neuropsychiatric, and physical symptoms. Studies to date cannot refute or confirm this syndrome as a nosological entity. If it actually exists, it seems to occur in susceptible people, even if exposed to small doses and for short periods, and symptoms may persist for long periods. Based on currently available data, the use of 5α-reductase inhibitors in patients with a history of depression, sexual dysfunction, or infertility should be carefully and individually assessed.


Assuntos
Humanos , Masculino , Disfunções Sexuais Fisiológicas/induzido quimicamente , Finasterida/efeitos adversos , Inibidores de 5-alfa Redutase/efeitos adversos , Espermatozoides/efeitos dos fármacos , Síndrome , Doenças Cardiovasculares/induzido quimicamente , Fatores de Risco , Infertilidade/induzido quimicamente , Transtornos Mentais/induzido quimicamente , Doenças Metabólicas/induzido quimicamente
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA